Full-Time

Ophthalmology Account Executive

ANI Pharmaceuticals

ANI Pharmaceuticals

501-1,000 employees

Develops, manufactures, markets prescription drugs

Compensation Overview

$160k - $200k/yr

+ Short-term incentive program + Long-term incentive program

Houston, TX, USA

Remote

Remote within the United States, covering Houston and potentially a multi-state territory; travel of 50%+ may be required.

Bachelor's, Master's

Category
Sales & Account Management (1)
Required Skills
Sales

Get referred to ANI Pharmaceuticals

See people who can refer or advise you

Requirements
  • A bachelor's degree is required.
  • At least 5 years of demonstrated success in rare disease, retina, and/or specialty pharmaceutical sales is required.
  • Understanding and experience working with in-house patient support services is required.
  • Familiarity with relevant legal and regulatory pharmaceutical industry requirements is required.
  • Experience leading and executing territory-level business planning activities is required.
  • A driver's license is required, with the ability to travel 50% or more as needed and take occasional overnight trips.
  • Must be able to work evenings and weekends as needed for physician or patient events, both in person and virtually.
  • Depending on geography, must be able to manage a multi-state territory with a diverse customer base.
Responsibilities
  • Drive demand through clinical selling and education for referring and treating health care providers on Cortrophin Gel and ILUVIEN.
  • Build and execute territory strategy and account-specific plans to drive physician and patient identification, market development, and brand awareness in Ophthalmology and Retina, while continuously assessing sales opportunities within markets and accounts to maintain and grow the business.
  • Prioritize and manage resources, activities, and time to optimize access to and development of accounts with the most sales potential.
  • Build individual account plans for key accounts and physicians, including approaches for engaging customers and maximizing sales results.
  • Build and maintain relationships with physicians through pre-call planning, customized call plans, and post-call analysis to refine and enhance the approach.
  • Collaborate with the Ophthalmology brand team and facilitate collaboration with MSLs, the Market Access team, the patient HUB, and other internal stakeholders to help ensure patient access and appropriate logistics for Cortrophin Gel and ILUVIEN.
  • Partner externally with key accounts and physicians to drive patient identification through market development and physician education, and develop a territory strategy to retain customers.
  • Demonstrate the highest standards of integrity and compliance.
  • Perform other duties as assigned.
Desired Qualifications
  • Extensive experience calling on Retina Specialists, Ophthalmologists, and Eye Care Professionals is strongly preferred.
  • Sales experience within multiple ophthalmology subspecialty areas is preferred.
  • Product launch experience, including working knowledge of government and commercial payers, is a plus.
  • Understanding of the buy-and-bill process, patient services, and specialty channel distribution is preferred.
  • An advanced degree in business or science is preferred.

ANI Pharmaceuticals develops, manufactures, and markets prescription medications, including generic and branded products, that are FDA-approved. Its medicines are produced in regulated facilities and go through standard safety and efficacy testing to meet patient needs. The company sells these products to pharmacies, hospitals, and healthcare providers, using a portfolio that spans generic drugs and specialty branded therapies. What sets ANI apart is its combination of a diversified product lineup with growth through strategic acquisitions to expand its offerings and market reach, rather than relying on a single product area. Its goal is to provide high-quality medicines to patients while continuously expanding its portfolio and market presence through acquisitions and manufacturing capabilities.

Company Size

501-1,000

Company Stage

IPO

Headquarters

Baudette, Minnesota

Founded

1996

Get referred to ANI Pharmaceuticals

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Q2 2026 revenue hit $266 million, and management reaffirmed $1.08-$1.14 billion guidance.
  • July 2026 was the highest month for new Cortrophin cases, signaling demand acceleration.
  • Repurchased-capable cash generation reached $360.2 million, funding acquisitions and buybacks through May 2029.

What critics are saying

  • Cortrophin 2026 guidance fell to $520-$540 million, exposing second-half execution risk.
  • Merck royalty burden stays in the high-20% range, compressing Cortrophin margins.
  • CG Oncology litigation still lingers after the July 29, 2025 no-damages verdict, risking distraction.

What makes ANI Pharmaceuticals unique

  • Cortrophin Gel drove 43.5% Q2 2026 growth, with rare disease becoming ANI's core.
  • ANI pairs U.S. manufacturing with 116 products, supporting branded, generic, and specialty breadth.
  • Henry Gosebruch joined August 19, 2026, bringing AbbVie M&A discipline to transformation.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

401(k) Retirement Plan

Unlimited Paid Time Off

Paid Vacation

Paid Holidays

Employee Stock Purchase Plan

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

-3%

2 year growth

23%
Yahoo Finance
Aug 28th, 2026
ANI Pharmaceuticals shows 36% revenue growth but limited scale at $978M

ANI Pharmaceuticals trades at $76.15 per share, showing a 3% return over six months, underperforming the S&P 500's 11.7% gain. The company develops, manufactures, and markets branded and generic prescription pharmaceuticals with a portfolio of 116 products. The pharmaceutical firm demonstrated strong momentum with revenue growing at 35.6% compound annual growth rate over five years. Its free cash flow margin expanded by 38.5 percentage points during the same period, reaching 17.7% over the trailing 12 months. However, ANI Pharmaceuticals faces scale challenges with just $978.4 million in revenue over the past year. This smaller size limits its ability to build customer trust in the heavily regulated healthcare sector, though it allows for faster potential growth with proper execution.

Yahoo Finance
Aug 24th, 2026
ANI Pharmaceuticals targets $1.6B market cap with 34.7% revenue growth, while Revolve and ProPetro face challenges

ANI Pharmaceuticals, a developer and marketer of branded and generic prescription drugs with a focus on rare disease treatments, stands out among Russell 2000 stocks. The company's portfolio includes 116 pharmaceutical products. ANI delivered 34.7% annual revenue growth over the past two years, indicating market share gains. Earnings per share increased 19.9% annually over five years, outperforming peers. The company's free cash flow margin improved by 38.5 percentage points over five years, providing resources for growth initiatives, share buybacks, or dividends. Meanwhile, fashion retailer Revolve and hydraulic fracturing services provider ProPetro face challenges. Revolve's 6.6% annual sales growth and 6.5% customer growth over three years underperformed, whilst high marketing expenses suggest heavy spending on customer acquisition. ProPetro's modest revenue base and declining EBITDA margin limit its competitiveness.

Yahoo Finance
Aug 24th, 2026
ANI Pharmaceuticals appoints Henry Gosebruch to board amid rare disease company transformation

ANI Pharmaceuticals has appointed Henry Gosebruch to its board of directors, effective 19 August 2026. Gosebruch brings over 30 years of experience in corporate strategy, business development, and finance across the biopharmaceutical sector. He currently serves as chief executive officer of Lakefront Biotherapeutics and previously held leadership positions at Neumora Therapeutics and AbbVie, where he oversaw more than 100 transactions including AbbVie's acquisition of Allergan. Before that, he spent over 20 years at J.P. Morgan as co-head of North American M&A. The appointment aims to strengthen ANI's board as the company accelerates its transformation into a rare disease-focused business. Muthusamy Shanmugam has resigned from the board but will continue as head of research and development and chief operating officer of New Jersey operations.

Yahoo Finance
Aug 16th, 2026
ANI Pharmaceuticals beats Q2 estimates with $266M revenue despite market concerns over Cortrophin guidance

ANI Pharmaceuticals reported second-quarter revenue of $266 million, beating analyst estimates of $259.8 million with 25.9% year-on-year growth. The company's adjusted EPS of $2.21 also surpassed expectations of $2.04. Despite strong performance in rare disease and generics businesses, the market reacted negatively to the results. CEO Nikhil Lalwani highlighted momentum in the third quarter, noting July marked the highest month for new cases initiated. The company reconfirmed its full-year revenue guidance of $1.11 billion at the midpoint and maintained its adjusted EPS guidance of $9.44. Operating margin improved to 15.2%, up from 6.6% in the same quarter last year. Analysts questioned the disconnect between prescription data and revenue, insurance reverification issues, and the rationale behind lowering Cortrophin guidance despite positive demand metrics.

Yahoo Finance
Aug 15th, 2026
ANI Pharmaceuticals posts 26% revenue growth but shares fall 9% on weak guidance

ANI Pharmaceuticals reported Q2 revenues of $266 million, up 25.9% year on year, exceeding analyst expectations by 2.4%. The company beat EPS estimates but slightly missed full-year revenue guidance expectations. Despite posting the fastest revenue growth among the four generic pharmaceuticals stocks tracked, ANI's shares fell 9.1% following the results. The company's portfolio includes 116 pharmaceutical products with a focus on rare disease treatments. Generic pharmaceuticals companies as a group delivered strong Q2 results, with revenues beating consensus estimates by 2.6%. However, the sector has struggled recently, with share prices down 5.6% on average since the latest earnings announcements. The industry faces pricing pressures and thin margins but benefits from consistent demand for affordable medications.